Ai integration and real-world utility of caredx portfolio highlighted in new data at the 2024 american transplant congress

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data to be presented at the 2024 american transplant congress (atc) being held june 1-5 in philadelphia. caredx solutions are featured in 36 oral presentations and posters, and a symposiu.
CDNA Ratings Summary
CDNA Quant Ranking